date,title,source
Oct-18-18,Rocket Pharmaceuticals Presents Updated Long-Term Phase 1/2 Clinical Data of RP-L102 in Fanconi Anemia Patients at the 2018 Annual Congress of the European Society of Gene and Cell Therapy (ESGCT),Business Wire
Oct-19-18,Rocket Pharmaceuticals Presents Preclinical Data at the 2018 Annual Congress of the European Society of Gene and Cell Therapy (ESGCT),Business Wire
Nov-01-18,Rocket Pharmaceuticals Announces Participation at Upcoming Conferences,Business Wire
Nov-07-18,Rocket Pharmaceuticals Reports Third Quarter 2018 Financial Results and Operational Highlights,Business Wire
Nov-07-18,Rocket Pharmaceuticals Announces FDA Clearance of IND Application for RP-L102 Gene Therapy for Fanconi Anemia,Business Wire
Nov-19-18,Rocket Pharmaceuticals Announces Clearance of IND for RP-L201 Gene Therapy for Leukocyte Adhesion Deficiency-I (LAD-I),Business Wire
Nov-26-18,Rocket Pharmaceuticals Announces Proposed Public Offering of Common Stock,Business Wire
Nov-26-18,"Rocket Pharmaceuticals Announces Preclinical Data for AAV-Based RP-A501, the First Investigational Gene Therapy Program for a Monogenic Heart Failure Syndrome",Business Wire
Nov-26-18,Rocket Pharmaceuticals and REGENXBIO Announce New License Agreement for the Treatment of Danon Disease Using NAV AAV9 Vector,Business Wire
Nov-26-18,REGENXBIO and Rocket Pharmaceuticals Announce New License Agreement for the Treatment of Danon Disease Using NAV AAV9 Vector,PR Newswire
Nov-27-18,Rocket Pharmaceuticals Prices Public Offering of Common Stock,Business Wire
Nov-27-18,Rocket Pharmaceuticals (RCKT) in Focus: Stock Moves 7.2% Higher,Zacks
Nov-27-18,Rocket Pharmaceuticals Receives FDA Regenerative Medicine Advanced Therapy (RMAT) and Fast Track Designations for RP-L102 Gene Therapy for Fanconi Anemia,Business Wire
Nov-28-18,Leerink Starts Coverage Of Genetic Medicine Stocks: 'We See Commercial Execution As Increasingly Driving Returns',Benzinga
Nov-30-18,Rocket Pharmaceuticals Announces Closing of Public Offering and Full Exercise of the Underwriters Option to Purchase Additional Shares,Business Wire
